Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of inactivated SARS-CoV-2 vaccine (Vero cell) in adults
PACTR202201773975686Phase 3Not yet recruiting
- Sponsor
- Institute of Medical Biology Chinese Academy of Medical Sciences
- Start
- Feb 2022
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sars-cov-2 vaccine inactivated vero cell in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Institute of Medical Biology Chinese Academy of Medical Sciences. Primary endpoints: Efficacy against symptomatic laboratory-confirmed COVID-19 and Solicited adverse events within 7 days after each dose. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
sars-cov-2 vaccine inactivated vero cell
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202201773975686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202201773975686.